ArticlePain reports2025
Cellular and molecular characterisation of the peripheral immune environment in migraine.
Article in Pain reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated Identification of NAD⁺ Metabolism-Associated Candidate Genes.Molecular neurobiology · 2026Article
- Migraine immune cell gene targets and their relationship to psychiatric disorders.The journal of headache and pain · 2026Article
- Plasma proteomics identifies proteins and pathways associated with incident migraine in 50,668 adults.The journal of headache and pain · 2026Article
- Peripheral immunosuppressive and immunostimulatory signatures of severity and pain in spinal cord injury.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Peripheral immune dysfunction may be critically involved in the pathophysiology of migraine. Some evidence supports a role for peripheral T cells, monocytes, and humoral factors including kynurenine metabolites and cytokines, however a comprehensive picture has yet to emerge. Objective: This study sought to undertake a systematic assessment of the immune changes in episodic and chronic migraine across phases of the migraine cycle. Methods: Migraine patients in different phases of the migraine cycle with a confirmed diagnosis of episodic or chronic migraine and age- and sex-matched healthy controls were recruited. Peripheral blood was assessed for circulating immune cells, plasma proteins, and kynurenine pathway metabolites in a cross-sectional case-control design. Data were acquired using high-dimensional approaches including proteomics, single-cell mass cytometry, and imaging flow cytometry. Results: Plasma proteins related to increased cell-cell adhesion and altered enzymatic activity were increased in migraine. The migraine prodrome displayed a strong and distinct proinflammatory phenotype defined by increased platelet-neutrophil aggregation, quinolinic acid production, and matrix metalloproteinase-9 expression. Migraine patients in the attack phase instead expressed higher levels of cytokine receptors and phosphorylated transcription factors in Th17 cells, monocytes, natural killer cells, and B cells. T cells were shifted to a mobilised, recirculating phenotype across all migraine phases. Episodic and chronic migraine patients were only distinguished by subtle changes in T-cell phenotype. Conclusion: Distinct proinflammatory peripheral signatures were detected between migraine phases, while few alterations distinguished episodic and chronic status. These data provide a resource that may aid in the identification of peripheral immune cells and mediators contributing to migraine attack onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.